Fresenius expands venture with ML Laboratories (UK):
This article was originally published in Clinica
Fresenius (Germany) and ML Laboratories (UK) have entered into a provisional agreement to expand their joint activities in peritoneal dialysis. The companies will set up two joint ventures: one in Germany, 20%-owned by ML, to target the continental European isodextrin-solution peritoneal dialysis market; and a second, 75%-owned by ML, in the UK. Fresenius will also obtain the exclusive US distribution rights for isodextrin solutions in the US. The two companies originally signed a joint deal in March 1993 (see Clinica No 593, p 13).